<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2015-10-22" updated="2020-01-02">
  <drugbank-id primary="true">DB09222</drugbank-id>
  <name>Fibrinogen human</name>
  <description>Fibrinogen concentrate (human) is a hematological agent. It works by replacing a certain protein in the blood that helps with blood clotting. Fibrinogen (factor I) is a soluble plasma glycoprotein with a molecular weight of about 340 kDa. It is a physiological substrate for three enzymes: plasmin, factor XIIIa and thrombin. It is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.</description>
  <cas-number>9001-32-5</cas-number>
  <unii>N94833051K</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links>
      <link>
        <ref-id>L225</ref-id>
        <title>FDA label</title>
        <url>http://www.fda.gov/downloads/Biolog...ionatedPlasmaProducts/ucm094006.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>For the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.</indication>
  <pharmacodynamics>Fibrinogen replaces the missing, or low coagulation factor.</pharmacodynamics>
  <mechanism-of-action>Fibrinogen (factor I) is a soluble plasma glycoprotein with a molecular weight of about 340 kDa. The native molecule is a dimer and consists of three pairs of polypeptide chains (Aα, Bβ and γ). Fibrinogen is a physiological substrate of three enzymes: thrombin, factor XIIIa, and plasmin. During the coagulation process, thrombin cleaves the Aα and Bβ chains releasing fibrinopeptides A and B (FPA and FPB, respectively). FPA is separated rapidly and the remaining molecule is a soluble fibrin monomer (fibrin I). The slower removal of FPB results in formation of fibrin II that is capable of polymerization that occurs by aggregation of fibrin monomers. The resulting fibrin is stabilized in the presence of calcium ions and by activated factor XIII, which acts as a transglutaminase. Factor XIIIa-induced cross-linking of fibrin polymers renders the fibrin clot more elastic and more resistant to fibrinolysis. Cross-linked fibrin is the end result of the coagulation cascade, and provides tensile strength to a primary hemostatic platelet plug and structure to the vessel wall.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption>Cmax is 140 mg/dL</absorption>
  <half-life>78.7 hours</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution>Mean volume of distribution is 52.7 mL/kg.</volume-of-distribution>
  <clearance>0.59 mL/h/kg</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Coagulation Factor I</synonym>
    <synonym language="english" coder="">Factor I (fibrinogen)</synonym>
    <synonym language="english" coder="">Factor I human</synonym>
    <synonym language="english" coder="">Fibrinogen</synonym>
    <synonym language="english" coder="">Fibrinogen (human)</synonym>
    <synonym language="english" coder="">Fibrinogen Concentrate (Human)</synonym>
    <synonym language="english" coder="">Fibrinogen concentrate human</synonym>
    <synonym language="english" coder="">Fibrinogen human</synonym>
    <synonym language="english" coder="">Fibrinogen human plasma-derived</synonym>
    <synonym language="english" coder="">Fibrinogen, human</synonym>
    <synonym language="english" coder="">Human fibrinogen</synonym>
  </synonyms>
  <products>
    <product>
      <name>Artiss</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02326167</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-12-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Artiss</name>
      <labeller>Baxalta US Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0944-4351</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-21</started-marketing-on>
      <ended-marketing-on>2008-03-21</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA125266</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ARTISS Fibrin Sealant</name>
      <labeller>Baxter Healthcare Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0338-8503</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA125266</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ARTISS Frozen</name>
      <labeller>Baxalta US Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0944-8503</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-03-19</started-marketing-on>
      <ended-marketing-on>2019-06-30</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA125266</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Evarrest</name>
      <labeller>Ethicon, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63713-050</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA125392</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Evarrest</name>
      <labeller>Omrix Biopharmaceuticals N. V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002515</ema-product-code>
      <ema-ma-number>EU/1/13/868/001</ema-ma-number>
      <started-marketing-on>2013-09-25</started-marketing-on>
      <ended-marketing-on>2018-04-03</ended-marketing-on>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Evarrest</name>
      <labeller>Omrix Biopharmaceuticals N. V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002515</ema-product-code>
      <ema-ma-number>EU/1/13/868/002</ema-ma-number>
      <started-marketing-on>2013-09-25</started-marketing-on>
      <ended-marketing-on>2018-04-03</ended-marketing-on>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Evicel</name>
      <labeller>Omrix Biopharmaceuticals Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02348497</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Solution</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>EVICEL Fibrin Sealant (Human)</name>
      <labeller>Ethicon Inc</labeller>
      <ndc-id/>
      <ndc-product-code>63713-390</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA125010</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fibryga</name>
      <labeller>Octapharma USA Inc</labeller>
      <ndc-id/>
      <ndc-product-code>68982-347</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125612</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fibryga</name>
      <labeller>Octapharma Pharmazeutika Produktionsges M B H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02464616</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>1 g</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Quixil</name>
      <labeller>Omrix Biopharmaceuticals Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02283980</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Kit; Solution</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Raplixa</name>
      <labeller>Mallinckrodt Pharmaceuticals Ireland Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002807</ema-product-code>
      <ema-ma-number>EU/1/14/985/001</ema-ma-number>
      <started-marketing-on>2015-03-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Raplixa</name>
      <labeller>Mallinckrodt Pharmaceuticals Ireland Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002807</ema-product-code>
      <ema-ma-number>EU/1/14/985/002</ema-ma-number>
      <started-marketing-on>2015-03-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Raplixa</name>
      <labeller>Mallinckrodt Pharmaceuticals Ireland Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002807</ema-product-code>
      <ema-ma-number>EU/1/14/985/003</ema-ma-number>
      <started-marketing-on>2015-03-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Raplixa</name>
      <labeller>ProFibrix BV</labeller>
      <ndc-id/>
      <ndc-product-code>62238-008</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-22</started-marketing-on>
      <ended-marketing-on>2018-08-03</ended-marketing-on>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA125523</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>RiaSTAP</name>
      <labeller>CSL Behring GmbH</labeller>
      <ndc-id/>
      <ndc-product-code>63833-8915</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-16</started-marketing-on>
      <ended-marketing-on>2009-03-17</ended-marketing-on>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>1300 mg/50mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125317</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>RiaSTAP</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02393352</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>1000 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>RiaSTAP</name>
      <labeller>CSL Behring GmbH</labeller>
      <ndc-id/>
      <ndc-product-code>63833-891</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>1300 mg/50mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125317</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TachoSil</name>
      <labeller>Baxter Healthcare Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0338-8701</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA125351</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TachoSil</name>
      <labeller>Baxter Healthcare Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0338-8702</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA125351</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TachoSil</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0338-8703</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA125351</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TachoSil</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0944-8701</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-05</started-marketing-on>
      <ended-marketing-on>2020-05-31</ended-marketing-on>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA125351</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TachoSil</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0944-8702</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-05</started-marketing-on>
      <ended-marketing-on>2020-05-31</ended-marketing-on>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA125351</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TachoSil</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0944-8703</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-05</started-marketing-on>
      <ended-marketing-on>2020-05-31</ended-marketing-on>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA125351</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TachoSil</name>
      <labeller>Takeda</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02439042</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>TachoSil</name>
      <labeller>Takeda</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02439026</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>TachoSil</name>
      <labeller>Takeda</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02439034</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tisseel</name>
      <labeller>Baxalta US Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0944-4210</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-05-01</started-marketing-on>
      <ended-marketing-on>2019-01-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA103980</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tisseel</name>
      <labeller>Baxalta US Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0944-4211</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-05-01</started-marketing-on>
      <ended-marketing-on>2019-01-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA103980</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tisseel</name>
      <labeller>Baxalta US Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0944-4212</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-05-01</started-marketing-on>
      <ended-marketing-on>2019-02-28</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA103980</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tisseel</name>
      <labeller>Baxalta US Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0944-4301</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-05-01</started-marketing-on>
      <ended-marketing-on>2019-02-28</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA103980</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tisseel</name>
      <labeller>Baxalta US Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0944-4302</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-05-01</started-marketing-on>
      <ended-marketing-on>2019-01-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA103980</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tisseel</name>
      <labeller>Baxalta US Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0944-4303</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-05-01</started-marketing-on>
      <ended-marketing-on>2019-02-28</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA103980</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tisseel</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02326132</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-12-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tisseel</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02326175</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tisseel</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0944-4201</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-02-18</started-marketing-on>
      <ended-marketing-on>2015-04-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA103980</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TISSEEL Fibrin Sealant</name>
      <labeller>Baxter Healthcare Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0338-4210</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA103980</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TISSEEL Fibrin Sealant</name>
      <labeller>Baxter Healthcare Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0338-4211</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA103980</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TISSEEL Fibrin Sealant</name>
      <labeller>Baxter Healthcare Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0338-4212</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA103980</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TISSEEL Fibrin Sealant</name>
      <labeller>Baxter Healthcare Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0338-4301</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA103980</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TISSEEL Fibrin Sealant</name>
      <labeller>Baxter Healthcare Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0338-4302</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA103980</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TISSEEL Fibrin Sealant</name>
      <labeller>Baxter Healthcare Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0338-4303</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA103980</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TISSEEL Fibrin Sealant</name>
      <labeller>Baxter Healthcare Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0338-8402</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA103980</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TISSEEL Fibrin Sealant</name>
      <labeller>Baxter Healthcare Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0338-9560</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA103980</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TISSEEL Fibrin Sealant</name>
      <labeller>Baxter Healthcare Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0338-9564</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA103980</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TISSEEL Fibrin Sealant</name>
      <labeller>Baxter Healthcare Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0338-9568</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA103980</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TISSEEL Frozen</name>
      <labeller>Baxalta US Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0944-8402</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-05-01</started-marketing-on>
      <ended-marketing-on>2019-07-31</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA103980</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vistaseal</name>
      <labeller>GRIFOLS USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>61953-0011</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA125640</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vistaseal</name>
      <labeller>GRIFOLS USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>61953-0012</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA125640</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vistaseal</name>
      <labeller>GRIFOLS USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>61953-0013</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA125640</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vistaseal</name>
      <labeller>GRIFOLS USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>61953-0014</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Topical</route>
      <fda-application-number>BLA125640</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Raplixa</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>Raplixa</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>Raplixa</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>Evarrest</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>Evarrest</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>Quixil</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>Raplixa</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>TachoSil</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>TachoSil</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>TachoSil</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>Tisseel</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>TachoSil</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>RiaSTAP</name>
      <ingredients>Fibrinogen human</ingredients>
    </mixture>
    <mixture>
      <name>Artiss</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>ARTISS Frozen</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>Evarrest</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>Tisseel</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>Tisseel</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>Tisseel</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>Tisseel</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>Tisseel</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>Tisseel</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>TISSEEL Frozen</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>ARTISS Fibrin Sealant</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>TISSEEL Fibrin Sealant</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>TISSEEL Fibrin Sealant</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>TISSEEL Fibrin Sealant</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>TISSEEL Fibrin Sealant</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>TISSEEL Fibrin Sealant</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>TISSEEL Fibrin Sealant</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>TISSEEL Fibrin Sealant</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>TISSEEL Fibrin Sealant</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>TISSEEL Fibrin Sealant</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>TISSEEL Fibrin Sealant</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>Fibryga</name>
      <ingredients>Fibrinogen human</ingredients>
    </mixture>
    <mixture>
      <name>RiaSTAP</name>
      <ingredients>Fibrinogen human</ingredients>
    </mixture>
    <mixture>
      <name>TachoSil</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>TachoSil</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>Vistaseal</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>Vistaseal</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>Vistaseal</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>Vistaseal</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>EVICEL Fibrin Sealant (Human)</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>Evicel</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>TachoSil</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>TachoSil</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>RiaSTAP</name>
      <ingredients>Fibrinogen human</ingredients>
    </mixture>
    <mixture>
      <name>TachoSil</name>
      <ingredients>Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>Fibryga</name>
      <ingredients>Fibrinogen human</ingredients>
    </mixture>
    <mixture>
      <name>Tisseel</name>
      <ingredients>Aprotinin + Calcium chloride + Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>Artiss</name>
      <ingredients>Aprotinin + Calcium chloride + Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>Tisseel</name>
      <ingredients>Aprotinin + Calcium chloride + Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Acute-Phase Proteins</category>
      <mesh-id>D000209</mesh-id>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Blood and Blood Forming Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Blood Coagulation Factors</category>
      <mesh-id>D001779</mesh-id>
    </category>
    <category>
      <category>Blood Proteins</category>
      <mesh-id>D001798</mesh-id>
    </category>
    <category>
      <category>Fibrinogen</category>
      <mesh-id>D005340</mesh-id>
    </category>
    <category>
      <category>Hemostatics</category>
      <mesh-id>D006490</mesh-id>
    </category>
    <category>
      <category>Increased Coagulation Activity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Protein Precursors</category>
      <mesh-id>D011498</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Solution</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Patch</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Intravenous</route>
      <strength>20 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>1 g</strength>
    </dosage>
    <dosage>
      <form>Kit; solution</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>1300 mg/50mL</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>1000 mg</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form/>
      <route>Topical</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="B02BB01">
      <level code="B02BB">Fibrinogen</level>
      <level code="B02B">VITAMIN K AND OTHER HEMOSTATICS</level>
      <level code="B02">ANTIHEMORRHAGICS</level>
      <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>20:28.16</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB09222.pdf?1445543703</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00058</drugbank-id>
      <name>Alpha-1-proteinase inhibitor</name>
      <description>The therapeutic efficacy of Fibrinogen human can be increased when used in combination with Alpha-1-proteinase inhibitor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00170</drugbank-id>
      <name>Menadione</name>
      <description>The therapeutic efficacy of Fibrinogen human can be increased when used in combination with Menadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00302</drugbank-id>
      <name>Tranexamic acid</name>
      <description>The therapeutic efficacy of Fibrinogen human can be increased when used in combination with Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06692</drugbank-id>
      <name>Aprotinin</name>
      <description>The therapeutic efficacy of Fibrinogen human can be increased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11091</drugbank-id>
      <name>Hydrogen peroxide</name>
      <description>The therapeutic efficacy of Fibrinogen human can be increased when used in combination with Hydrogen peroxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13244</drugbank-id>
      <name>Aminomethylbenzoic acid</name>
      <description>The therapeutic efficacy of Fibrinogen human can be increased when used in combination with Aminomethylbenzoic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13729</drugbank-id>
      <name>Camostat</name>
      <description>The therapeutic efficacy of Fibrinogen human can be increased when used in combination with Camostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00513</drugbank-id>
      <name>Aminocaproic acid</name>
      <description>The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Fibrinogen human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12726</drugbank-id>
      <name>Monteplase</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Monteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00001</drugbank-id>
      <name>Lepirudin</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00006</drugbank-id>
      <name>Bivalirudin</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00009</drugbank-id>
      <name>Alteplase</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00013</drugbank-id>
      <name>Urokinase</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00015</drugbank-id>
      <name>Reteplase</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00029</drugbank-id>
      <name>Anistreplase</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00031</drugbank-id>
      <name>Tenecteplase</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00054</drugbank-id>
      <name>Abciximab</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Abciximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00055</drugbank-id>
      <name>Drotrecogin alfa</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Drotrecogin alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00086</drugbank-id>
      <name>Streptokinase</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Streptokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Anagrelide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Dicoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00278</drugbank-id>
      <name>Argatroban</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Argatroban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00407</drugbank-id>
      <name>Ardeparin</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Ardeparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Fondaparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00686</drugbank-id>
      <name>Pentosan polysulfate</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Pentosan polysulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Acetylsalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Phenprocoumon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Dipyridamole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Iloprost.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Heparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01225</drugbank-id>
      <name>Enoxaparin</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Enoxaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Epoprostenol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Acenocoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03410</drugbank-id>
      <name>4-hydroxycoumarin</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with 4-hydroxycoumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04665</drugbank-id>
      <name>Coumarin</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Coumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04898</drugbank-id>
      <name>Ximelagatran</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Ximelagatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04925</drugbank-id>
      <name>Desmoteplase</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Desmoteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04932</drugbank-id>
      <name>Defibrotide</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Defibrotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05099</drugbank-id>
      <name>Ancrod</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Ancrod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05229</drugbank-id>
      <name>Beraprost</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Beraprost.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05254</drugbank-id>
      <name>Fibrinolysin</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Fibrinolysin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Prasugrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Rivaroxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Sulodexide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06406</drugbank-id>
      <name>Idraparinux</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Idraparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06441</drugbank-id>
      <name>Cangrelor</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Cangrelor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06543</drugbank-id>
      <name>Astaxanthin</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Astaxanthin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Apixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06635</drugbank-id>
      <name>Otamixaban</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Otamixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06679</drugbank-id>
      <name>Amediplase</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Amediplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06754</drugbank-id>
      <name>Danaparoid</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Danaparoid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Dalteparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06822</drugbank-id>
      <name>Tinzaparin</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Tinzaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07767</drugbank-id>
      <name>Ferulic acid</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Ferulic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with (R)-warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Ethyl biscoumacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08813</drugbank-id>
      <name>Nadroparin</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Nadroparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08814</drugbank-id>
      <name>Triflusal</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Triflusal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08816</drugbank-id>
      <name>Ticagrelor</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Ticagrelor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08994</drugbank-id>
      <name>Ditazole</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Ditazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09030</drugbank-id>
      <name>Vorapaxar</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Vorapaxar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Edoxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09125</drugbank-id>
      <name>Potassium citrate</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Potassium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09154</drugbank-id>
      <name>Sodium citrate</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09255</drugbank-id>
      <name>Dextran</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Dextran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09258</drugbank-id>
      <name>Bemiparin</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Bemiparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09259</drugbank-id>
      <name>Reviparin</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Reviparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09260</drugbank-id>
      <name>Parnaparin</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Parnaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09261</drugbank-id>
      <name>Certoparin</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Certoparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11095</drugbank-id>
      <name>Desirudin</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Desirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11154</drugbank-id>
      <name>Zinc citrate</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Zinc citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11166</drugbank-id>
      <name>Antithrombin Alfa</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Antithrombin Alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11312</drugbank-id>
      <name>Protein C</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Protein C.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11598</drugbank-id>
      <name>Antithrombin III human</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Antithrombin III human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11984</drugbank-id>
      <name>Letaxaban</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Letaxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12289</drugbank-id>
      <name>Darexaban</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Darexaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12364</drugbank-id>
      <name>Betrixaban</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Betrixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12598</drugbank-id>
      <name>Nafamostat</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12831</drugbank-id>
      <name>Gabexate</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Gabexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Fluindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13149</drugbank-id>
      <name>Protein S human</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Protein S human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13199</drugbank-id>
      <name>Brinase</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Brinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13275</drugbank-id>
      <name>Clorindione</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Clorindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13347</drugbank-id>
      <name>Diphenadione</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Diphenadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13451</drugbank-id>
      <name>Tioclomarol</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Tioclomarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13616</drugbank-id>
      <name>Melagatran</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Melagatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13646</drugbank-id>
      <name>Saruplase</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Saruplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with (S)-Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14094</drugbank-id>
      <name>Tocopherylquinone</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Tocopherylquinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14598</drugbank-id>
      <name>Edetate calcium disodium anhydrous</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Edetate calcium disodium anhydrous.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14600</drugbank-id>
      <name>Edetate disodium anhydrous</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Edetate disodium anhydrous.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14726</drugbank-id>
      <name>Dabigatran</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Dabigatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06294</drugbank-id>
      <name>Semuloparin</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Semuloparin.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>17119</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>20462</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347910418</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Fibrin_glue</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/ppa/fibrinogen-concentrate-human.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>